Eligibility: Dogs with confirmed lymphoma are eligible for this study.  Dogs must undergo some diagnostic testing prior to
starting the study to ensure that they are eligible, including bloodwork (complete blood count, chemistry profile) and
urinalysis. Chest X-rays are strongly recommended.  Dogs must have good function of liver and kidneys, have acceptable
blood cell counts, and be free of severe underlying disease.  

Summary: Lymphoma is one of the most common cancers in dogs.  Current treatment options include various types of
chemotherapy; however, there are no approved drugs for lymphoma in dogs, very few dogs are cured and most will relapse.  
New drugs remain necessary to treat these drug-resistant relapses.

Tanovea (Rabacfosadine) is an intravenous chemotherapy agent that has been used both in normal dogs and in more than
80 dogs with cancer.  It has been shown to induce remission in 60 to 100% of dogs with lymphoma.  The goal of this study is
to evaluate the effectiveness of Tanovea (Rabacfosadine) given once every 21 days.

Requirements: Initially your pet will undergo a series of diagnostic tests, which may include blood tests, urinalysis, a fine
needle aspirate of a representative lymph node, and chest X-rays.  The results of these initial tests will determine if your pet
is eligible to enter this clinical trial.  These tests are part of the routine testing done in patients with lymphoma, and may be
performed even if you decide that your pet will not participate.  Your dog will then receive an injection of Tanovea
(Rabacfosadine) every 3 weeks for up to 5 treatments.  Rechecks will be required 1 week after the first treatment, and
possibly 1 week following the second treatment, depending on whether side effects are noted or not.  This study is not
randomized and there is no placebo group – all dogs will receive Tanovea  (Rabacfosadine).

Your pet may experience side effects.  Side effects may be mild or serious, including the risk of death.  Treatment with
Tanovea (Rabacfosadine) may result in gastrointestinal upset (decreased appetite, vomiting, diarrhea) and decreases in the
white blood cell count.  Tanovea (Rabacfosadine) may also cause hair loss, skin reddening, itchiness and pain after multiple
doses.  These effects go away when treatment with Tanovea (Rabacfosadine) is stopped.  A small number of dogs have
developed scarring of the lungs after completion of treatment.  Everyone involved in your pet’s care will monitor carefully for
side effects.  Your pet’s oncology clinician may prescribe medications, delay treatment or reduce the dosage of Tanovea
(Rabacfosadine) to help lessen side effects.

Your pet’s oncology clinician will discuss possible side effects with you.  If your pet experiences anything unusual during the
clinical trial, please contact the oncology clinician or Clinical Trials team.

Owner Responsibilities: You are expected to make and keep all appointments according to the study protocol.  You must be
comfortable administering oral medications at home, and you must be committed to completing the entire study protocol and
follow-up examinations.

Financial incentive: Clients participating in this study will be given special financial considerations.  Rabacfosadine will be
provided at no cost.  You will be responsible for the costs of the initial examination and tests to insure eligibility to participate,
the recheck examinations, blood tests, and ancillary medications.


INDIANA
Location: Purdue University Veterinary School of Medicine, West Lafayette, IN
Contact information:  Dr. Michael Childress at (765) 494-1107 or mochildr@purdue.edu, or you may contact Sarah Lahrman
at (765) 496-6289 or salahrma@purdue.edu
www.vet.purdue.edu/orpd/files/documents/clinical-trial-recruitments.pdf

Study #1: Use of new oral chemotherapy agent MLN0415
Description: This study involves the use of a new oral chemotherapy agent (MLN0415) which inhibits kappa B kinase(IKK);
known to contribute to cancer progression and drug resistance in human lymphomas. This pilot study is to determine whether
MLN0415 has activity against untreated or relapsed canine multicentric lymphoma.

Eligibility:
  • Biopsy confirmed high-grade multicentric lymphoma.
  • Measurable peripheral lymph nodes
  • Expected survival time of at least 4 weeks
  • Absence of significant symptoms of illness
  • Absence of other serious diseases.

Financial incentive: MLN0415 will be provided at no charge.

Study #2: Dogs with lymphoma that have failed or relapsed following treatment
Description: The purpose of this pilot study is to assess the anti-tumor efficacy of carboplatin in dogs that have failed or
relapsed following treatment of at least 1 other chemotherapy protocol

Eligibility:
  • Biopsy –confirmed high-grade multicentric lymphoma
  • Cancer relapse following treatment
  • Expected survival ≥ 4 weeks
  • Normal CBC and serum creatinine ≤2 mg/dl

Financial incentive: Carboplatin drug and tru-cut biopsy cost covered by research funds.


Study #3: Dogs with lymphoma
Description: This multi-institutional trial, sponsored by the National Cancer Institute, assesses the safety and effectiveness of
three newly developed chemotherapy agents when given to dogs with lymphoma.

Eligibility:
  • Biopsy diagnosis of lymphoma
  • Absence of clinical signs of illness
  • Both newly diagnosed and relapsed lymphomas are eligible

Financial incentive: Costs associated with this study will be provided. Additional financial support will be provided after your
dog’s completion of this study for chemoptherapy/treatment at the Veterinary Teaching Hospital.


LOUISIANA
Study: Mitoxantrone versus Mitoxantrone + DTIC for dogs with refractory lymphoma who were
previously treated with chemotherapy
Location: Louisiana State University School of Veterinary Medicine, Baton Rouge, LA 70803
Phone: 225-578-9600
www.vetmed.lsu.edu/clinical_trials.htm

Eligibility: To be eligible for this study, your dog must meet the following criteria: confirmed diagnosis of lymphoma;
relapsed after initial treatment with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone), must
have never received mitoxantrone or DTIC chemotherapy and has not had chemotherapy for 14 days prior to initiating this
treatment.

Summary: The purpose of this study is to compare the efficacy of single-agent mitoxantrone to the combination of
mitoxantrone and DTIC, in dogs with CHOP-resistant lymphoma.


MASSACHUSETTS
Study #1: Investigation of IGF-1 axis in dogs with lymphoma
Location: Tufts University Cummings School of Veterinary Medicine, North Grafton, MA
Phone: Kelly Reed, Oncology Liaison; (508) 887-4682 or veterinaryoncology@tufts.edu
http://sites.tufts.edu/vetclinicaltrials/specialty/oncology/

Eligibility: Dogs with a confirmed diagnosis of multicentric lymphoma (cytology or pathology), weighing more than 25kg. Dogs
must be eating a commercial diet and be otherwise healthy.

Exclusion criteria: Dogs with other systemic diseases (diabetes mellitus, hypothyroidism, Cushing’s disease, kidney disease,
liver disease, etc). Dogs eating a home-cooked or raw diet.

Summary: Lymphoma is one of the most common cancers in the dog and is comparable to non-Hodgkin’s lymphoma in
humans. Chemotherapy is the standard of care for treatment and can provide long term disease control but survival beyond
2 years is rare. There is active investigation into the utility of metabolic markers, such as insulin-like growth factor 1 (IGF-1),
as a predictor of response to treatment in humans with non-Hodgkin’s lymphoma. Additionally these markers may serve as a
target for future therapy. The goal of this study is to assess levels of IGF-1 and other related blood biomarkers in canine
patients with lymphoma. We will evaluate these markers for prognostic value and will determine whether they could serve as
targets for therapy in the future.

Requirement and incentive: No direct benefits. Dog owners are financially responsible for the costs associated with cancer
staging plus standard chemotherapy and recommended treatment monitoring (weekly complete blood counts).

This study covers the cost of measurement of IGF-1 and other metabolites.


Study #2: Novel Chemotherapy for Canine Multicentric Lymphoma
Location: Tufts University Cummings School of Veterinary Medicine, North Grafton, MA
Phone: Kelly Reed, Oncology Liaison; (508) 887-4682 or veterinaryoncology@tufts.edu
http://sites.tufts.edu/vetclinicaltrials/specialty/oncology/

Eligibility:
  • Dogs of any age
  • Cytologically or histologically confirmed diagnosis of lymphoma involving multiple external lymph nodes
  • Dogs must be feeling well or only minimally compromised
  • Dogs either must not have received treatment for lymphoma for at least 2 weeks prior to enrollment in the study

Exclusion Criteria:
  • Significant illness (such as kidney failure, liver disease, heart failure, severe anemia)
  • Dogs weighing less than 33 pounds
  • Dogs who have received prednisone for any reason in the two weeks prior to study enrollment

Summary: This preclinical trial, sponsored by the National Cancer Institute, is designed to evaluate three new chemotherapy
agents in the indenoisoquinoline class. These drugs inhibit topoisomerase I, which is an enzyme important in DNA replication,
and have shown efficacy in a variety of cancers.

The intent of this study is to define and compare the pharmacologic effects of these three drugs in dogs with lymphoma.
Specifically, the study will assess basic properties of the drug, such as duration of action, markers of damage to DNA in
cancer cells, and safety. The goal is to determine the appropriate dose of each drug and to determine if there are
differences in biologic activity among the drugs. The response to treatment, specifically whether lymphoma goes into
remission in the treated dogs, will also be assessed.

Financial incentive: This study is fully funded and will cover the cost of treatment, monitoring tests and management of
treatment related side effects. Dogs that complete the 28-day study will be eligible to receive $1000 for further medical care
at Tufts.

Study #3: Investigation of a novel diet for support of dogs undergoing chemotherapy for mast cell tumors
or multicentric lymphoma
Location: Tufts University Cummings School of Veterinary Medicine, North Grafton, MA
Phone: To make an appointment with the oncology department please call the oncology liason, Kelly Reed at 508-887-4682.
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: diane.welsh@tufts.edu

http://sites.tufts.edu/vetclinicaltrials/specialty/oncology/

Eligibility: ◾Dogs > 1 year of age with multicentric lymphoma (LSA) and grade 2 or higher mast cell tumors (MCT) that will be
treated with standard (non-metronomic) chemotherapy protocols at a participating study site. ◾Weight > 5 kg,temperament
suitable for drawing blood without sedation, All dogs should be naïve to treatment for the current cancer, but can have been
treated for other cancers in the past if greater than 1 year prior.

Exclusion criteria: Other diseases expected to potentially decrease quality of life, alter survival time, or limit diet options – e.g.
significant heart disease, kidney disease, bad liver disease, etc.Current vomiting or diarrhea or a history of chronic vomiting
or diarrhea (more than 6 multi-day episodes per year or one month of consistent clinical signs) within the last year that
required medications or special diet for control. Dogs with anticipated life expectancy of < 4 months. Pet owner not willing to
feed prescribed diet and limit treats to 5% of calories.

Summary: Cancer is one of the most common conditions seen in older dogs and it is becoming more common for owners to
opt to treat their pets with chemotherapy.  Dogs undergoing chemotherapy may suffer from side effects of treatment such as
vomiting, diarrhea, and reduced appetite.  There are currently no commercial diets that are designed specifically to help
support dogs with cancer undergoing chemotherapy by reducing the gastrointestinal side effects of chemotherapy.The
purpose of the study is to determine whether a specially formulated diet may reduce gastrointestinal side effects associated
with chemotherapy and improve quality of life of dogs undergoing chemotherapy.

Dogs will be fed either a high quality control diet appropriate for dog maintenance or the specially designed study diet –
neither the pet owners nor the researchers will know which diet the dog is getting. Pet owners will need to fill out quality of life
surveys as well as diet journals and fecal score journals every 1-2 weeks, and bring their dogs in for study
visits/chemotherapy every 2 weeks. At three points during the study, blood and urine will be collected from fasted dogs.

Treats and dietary supplements will need to be restricted to only those provided on an approved treat and supplement list.

Financial incentive: The study will cover the costs of all study-related blood work and visits.  You will also receive free high
quality pet food for the two month study duration and a $300 credit towards your account balance when you and your dog
successfully complete the study and return all study-related paperwork.  The study does not include the costs of cancer
staging (including those required to determine study eligibility), or any costs associated with surgery or chemotherapy,
additional blood work not required for the study, or follow-up visits outside of those described above.  Your dog’s
participation will also allow us to gain information which will help in the management of other dogs undergoing chemotherapy.


MISSOURI
Study #1: Relapsed Refractory Lymphoma/Chronic Lymphocytic Leukemia Study
Location: University of Missouri, Columbia, MO
Phone:    573-882-7821
www.cvm.missouri.edu/oncology/current.html

Eligibility:
  • Refractory lymphoma or chronic lymphocytic leukemia
  • CBC, chemistry panel, UA
  • RRL dogs: NO comorbid conditions that would limit life expectancy to <9 weeks. Adequate renal, hepatic and
    hematopoietic perimeters. Performance score of 0-1.
  • CLL dogs-included if: lymphocyte count > 40,000 cells/uL and < 150,000 cells/uL, normal liver and kidney values and
    performance score of 0 with life expectancy of 3 months.

Summary: Relapsed Refractory Lymphoma/Chronic Lymphocytic Leukemia Study is a study that involves the use of the
cholesterol inhibitor terbinafine as a chemosensitizer to dogs with relapsed refractory lymphoma (RRL) receiving lomustine or
dogs with chronic lymphocytic leukemia (CLL) receiving terbinafine alone followed by terbinafine and chlorambucil. The
specific objectives of this study are to demonstrate tolerability and improved efficacy of lomustine in managing RRL when
dogs are concomitantly treated with terbinafine, to identify activity of terbinafine alone in dogs with CLL, to demonstrate
improved efficacy of chlorambucil in managing CLL when dogs are concomitantly treated with terbinafine, and to demonstrate
lipid membrane composition changes in lymphocytes of dogs treated with terbinafine

Procedures:
  • RRL- Terbinafine daily throughout study starting 7 days prior to starting lomustine. Lomustine every three weeks.
    Complete blood work prior to and one week post lomustine treatment.
  • CCL- Terbinafine daily for two months prior to starting chlorambucil on days 1-4 of each treatment week. Complete
    blood work prior to and every 4 weeks after start of therapy.

Incentives: Drugs are provided free to owner.   

Study #2: Lymphoma-PET  Study
Location: University of Missouri, Columbia, MO
Phone:    573-882-7821 (Dr.’s Sandra Axiak and Mike Lewis)
www.cvm.missouri.edu/oncology/current.html

Eligibility:
  • Canine lymphoma diagnosed by cytology or histopathology
  • NO Prednisone prior to scan
  • CBC, chemistry panel, UA, thoracic and abdominal radiographs, abdominal U/S.
  • 18F-FDG-PET scan and overnight stay in radiation isolation
  • Bone marrow aspirate next day following PET scan

Overview: For humans with lymphoma, FDG positron emission tomography (18F-FDG-PET) has largely replaced CT
scanning to determine lymphoma stage for high-grade lymphomas, similar to those in dogs. In dogs, staging tests and criteria
have been inconsistently applied in the literature making precise prognostication difficult.  Replacing some or all of the
current staging procedures with a single, more sensitive procedure would improve standardization of stage determination
and potentially reduce expense and variability in test evaluation for dogs with lymphoma. The objective of this project is to
determine whether 18F-FDG-PET will perform equivalently with traditional staging tests for dogs with lymphoma.

Incentives: PET scan and related charges provided free of charge. Initial staging is owner’s responsibility.


PENNSYLVANIA
Study: Comparison of Three New Medications for Dogs with Lymphoma
Location: University of Pennsylvania Veterinary Hospital, Philadelphia, PA
If you are interested in learning more about this study, please contact the VCIC at 215-573-0302 or vcic@vet.upenn.edu
www.vet.upenn.edu/research/clinical-trials/clinical-trial/comparison-of-three-new-medications-for-dogs-with-lymphoma

Summary: The purpose of this study is to determine the safety and dose of 3 different chemotherapy drugs in dogs with
lymphoma.  Dogs with a confirmed diagnosis of lymphoma (just diagnosed or relapsed after treatment) with no other
significant health problems are eligible.  Each dog will receive 1 of the 3 chemotherapy drugs being evaluated, and
depending on how your dog responds to the drug, additional doses may be given.  

Procedures: The chemotherapy drug is given daily for 5 days, and your dog will stay at Penn Vet during that treatment
period.  You will be required to bring your dog back to Penn Vet after the treatment is completed for a minimum of 28 days.

Benefits: Once your dog is enrolled, costs associated with study-related sample collection, treatment with the study drug and
any side effects will be paid for by the study.  Owners will also receive a financial credit to apply towards future non-study
lymphoma treatment for their dog.


WISCONSIN
Study #1: Dogs with lymphoma
Location:  University of Wisconsin Veterinary Teaching Hospital, Madison, WI
Phone:  Dr. Kathleen Tsimbas or members of the Oncology Service at (608) 263-7600.
http://uwveterinarycare.wisc.edu/clinical-trials/oncology/

Summary: One of the trials, sponsored by the National Cancer Institute (NCI), assesses the safety and effectiveness of three
newly developed chemotherapy agents (indenoisoquinolines) when given to dogs with lymphoma. Studies in mice and non-
tumor-bearing dogs have shown indenoisoquinolines to be safe.  The study involves intravenous administration of an
indenoisoquinoline daily for 5 consecutive days. Blood samples, bone marrow biopsies, and tumor biopsies will be collected
prior to treatment and following the first and fifth treatment. The first week of this study will necessitate a minimum of 2 nights,
if not all, overnight boarding at the Hospital. Dogs will then return weekly for evaluation and subsequent blood collection (Day
8, 15, 22 and 29). Continuance on study beyond day 29 will be based on response to indenoisoquinoline therapy. Costs
associated with this study will be provided by the study. In addition, a gift of $1,000 (one thousand dollars) will be credited to
the owner’s UW Veterinary Care account. In the event any complications arise during the study period, their management will
be covered by study funds up to $2,000/per dog/per event. This would include any unanticipated hospitalizations.

Study #2: Dogs with lymphoma
Location:  University of Wisconsin Veterinary Teaching Hospital, Madison, WI
Phone:  Dr. Kathleen Tsimbas or members of the Oncology Service at (608) 263-7600.
http://uwveterinarycare.wisc.edu/clinical-trials/oncology/

Summary: The second trial is evaluating a novel biological therapy for lymphoma.  This agent is administered directly into an
accessible lymph node, once weekly for 4 treatments. This study requires an initial hospital stay of 2 days, then weekly visits
until treatment is completed, and then follow-up visits every 2 weeks.  All costs associated with this study will be provided by
the study. In addition, a gift of $500 (five hundred dollars) will be credited to the owner’s UW Veterinary Care account. In the
event any complications arise during the study period, their management will be covered by study funds. This would include
any unanticipated hospitalizations.

Study #3: Dogs with lymphoma
Location:  University of Wisconsin Veterinary Teaching Hospital, Madison, WI
Phone:  Dr. Kathleen Tsimbas or members of the Oncology Service at (608) 263-7600.
http://uwveterinarycare.wisc.edu/clinical-trials/oncology/

Summary: The third trial is evaluating VDC-1101 (previously called GS-9219), which is an intravenous chemotherapy agent
that has been used both in normal dogs and in more than 80 dogs with cancer. It has been shown to induce remission in 60
to 100% of dogs with lymphoma. The goal of this study is to evaluate the effectiveness of VDC-1101 given intravenously over
30 minutes, once every 21 days, along with a low dose of prednisone. VDC-1101 will be provided at no charge. All costs
related to drug administration, study evaluations, and management of adverse events will be paid for by the owner.
PET CANCER CENTER
Comprehensive guide to cancer diagnosis and treatment in cats and dogs
© 2007 Pet Cancer Center. ALL RIGHTS RESERVED.
Last updated 7/31/2016
Please take our short survey to help us understand pet owners' perception of clinical trials.
Open clinical
trials for dogs
Dog Fences Training and Bark Collars Pet Feeders
Pet Meds - Advantage
Pets Supplies and Gifts for Pet Lovers
Clinical trials for lymphoma in dogs
Find clinical trials for specific tumor types in dogs:

CALIFORNIA
Use of of diphenhydramine to reduce infusion-related ventricular arrhytmias in dogs treasted with
doxorubicin

Location: University of California, Davis
Contact: The Oncology Clinical Trial Coordinators via email (oncologyclinicaltrials@ucdavis.edu) or phone (530-752-0125 or
530-752-9759)
www.vetmed.ucdavis.edu/clinicaltrials/current_trials/by_species/dogs.cfm

Purpose: The aim of this study is to see if administration of diphenhydramine (commonly known as Benadryl) prior to
treatment with doxorubicin chemotherapy reduces the risk of arrhythmias (irregular rhythm) sometimes associated with the
administration of this chemotherapy
.  

IDogs diagnosed with lymphoma and undergoing treatment with the CHOP protocol at the UC Davis VMTH are eligible to
participate in this study.


Procedures: As part of this study your animal will receive the same diagnostic tests and care that any other dog presented to
the Oncology Service would receive. The only difference for study participants is that your dod may or may not receive an
anti-histamine drug (Benadryl) at the time of its 2st and 2nd doxorubicin treatments. Diphenhydramine can also be useful to
reduce the liberation of histamine molecules that can cause arrythmias. To evaluate the effects of diphenhydramine in this
regards, a portable and battery operated device that measures the heart's activity (Holter monitor) will be used. Dogs withll
wear the device for approximately 1 hour before and 3 hours after the infusion of chemothreapy, which may requre that your
dog stay in the hospital for a longer period of time than a traditional visit.


Owner Responsibilities: Once enrolled in the clinical trial, you are responsibal for scheduling and keeping all appointments
needed for study participation and reporting any side effects of the treatment to your doctor in a timely manner. If you agree
to have your dog participate in this study, a screening echocardiogram and your dog's Holter monitor, analyzed by aboard
certified veterinary cardiologist, will be performed at no charge to you. All other costs associated with the recommended
chemotherapy protocol and patient care will be your responsibility as they are not a part of this study.
.

Financial incentive: No benefits can be promised to your dog or other animals from your taking part in this clinical trial.
However, possible benefits include allowing the site to better guide medical care for your dog and future dogs affected with
the same disease. The understanding of your dog's electrocardiogram may guide medical decisions and this technology
(Holter monitoring) isfree charge for study participants.
.
VARIOUS LOCATIONS
Efficacy of Tanovea (Rabacfosadine) for Injection in Dogs with Lymphoma
For more information about the study, please click here

Primary study contact: Kara Hall at csuoncologytrials@colostate.edu or 970-297-4001.
www.csuanimalcancercenter.org/clinical-trials

Locations:
Colorado State University Animal Cancer Center, Fort Collins, Colorado (970-297-4195)
Southwest Veterinary Oncology - Tucson, Arizona
Veteirnary Specialty Hospital of San Diego - San Diego, California
University of California Davis - Davis, California
VRCC Veterinary Cancer Specialists - Englewood, Colorado
The Veterinary Cancer Center - Norwalk, Connecticut
University of Georgia - Athens, Georgia
University of Illinois - Urbana, Illinois
Tufts University - North Grafton, Massachusetts
University of Missouri - Columbia, Missouri
Red Bank Veterinary Hospital - Tinton Falls, New Jersey
Katonah Bedford Veterinary Center - Bedford Hills, New York
Ohio State University - Columbus, Ohio
Hope Veterinary Specialists - Malvern, Pennsylvania
Animal Diagnostics Clinic - Dallas, Texas
University of Wisconsin - Madison, Wisconsin